Oct 17 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Ardelyx's drug to treat high phosphate levels in patients with chronic kidney disease (CKD), the company said on Tuesday, more than two years after it was initially rejected.
(Reporting by Mariam Sunny, Khushi Mandowara and Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
The $50 million purchase could turn into Nvidia's biggest investment.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
Nancy Pelosi's husband Paul Pelosi uses an investing strategy that lowers upfront costs.
The tobacco giant will soon be allowed to sell a proven product in a proven market.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The yen's volatile episode may spread to other fiat currencies as U.S. rate cuts remain elusive amid sticky inflation, which could drive investors to gold and bitcoin, Noelle Acheson said in an interview.